Regular ophthalmologic examinations should constitute a non-negotiable component of treatment protocols, particularly for patients presenting with diabetes or pre-existing vascular conditions
For other Novo Nordisk medications, the threshold is 400% FPL (about $60,240 single)
Studies are also underway for a spectrum of other conditions, including Phase 3 trials investigating non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), and obstructive sleep apnea (OSA), as well as mid-to-late stage trials exploring potential benefits in neurodegenerative disorders like Parkinsons disease
Supports whole-body health, including gut health, digestion, energy, and immune defense.* NSF Certified for Sport and third-party tested for hundreds of contaminants and banned substances to ensure rigorous quality and safety standards
Not necessarily, which is exactly the point